Heron Therapeutics is trading 5.23% lower at $0.29 after its September 29, 2026, close at $0.31; available coverage does not establish a cause for the after-hours decline. - Shares rose 4.87% during the regular session. - After the close, Heron announced a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone that grants U.S. commercial rights and involves milestone and royalty payments. - Broader indices were little changed, so no clear market-wide explanation is evident.